1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cytosorbents Corporation

Cytosorbents Corporation

CTSO
Cytosorbents CorporationUS flagNASDAQ Capital Market
0.35
USD
+0.00
- -
22.00MMarket Cap

Total Valuation

Cytosorbents Corporation carries a market capitalization of 22.00M, placing it among publicly traded companies globally. Its enterprise value stands at 48.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap22.00M
Enterprise Value48.52M

Share Statistics

Cytosorbents Corporation currently has 62.84M shares outstanding.

Shares Outstanding62.84M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.63, and the price-to-book ratio stands at -31.30.

PE RatioN/A
PS Ratio0.63
PB Ratio-31.30
P/TBV Ratio-6.50
P/FCF Ratio-2.70
P/OCF Ratio-2.57

Enterprise Valuation

EV / Sales1.30
EV / EBITDAN/A
EV / EBITN/A
EV / FCF120.60

Financial Position

Cytosorbents Corporation maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -3,918.24, indicating conservative leverage, while an interest coverage ratio of -3.41 demonstrates limited ability to service its debt obligations.

Current Ratio0.66
Quick Ratio0.47
Debt / Equity-3,918.24
Debt / EBITDA-2.77
Interest Coverage-3.41

Financial Efficiency

Return on Equity (ROE)-334.15
Return on Assets (ROA)-42.38
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.86

Taxes

Income Tax-401,000.00
Effective Tax RateN/A

Stock Price Statistics

Cytosorbents Corporation's stock has declined approximately -64.36279% over the past 52 weeks. The 50-day moving average sits at 7.40, while the 200-day moving average is 11.15.

Beta (5Y)N/A
52-Week Price Change-64.36279%
50-Day Moving Average7.40
200-Day Moving Average11.15
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Cytosorbents Corporation generated 37.22M in revenue and converted that into -18.21M in net income, yielding earnings per share of -0.29. EBITDA reached -10.61M, while operating income came in at -12.15M.

Revenue37.22M
Gross Profit26.65M
Operating Income-12.15M
Pretax Income-18.61M
Net Income-18.21M
EBITDA-10.61M
EBIT-12.15M
Earnings Per Share (EPS)-0.29

Balance Sheet

Cytosorbents Corporation holds 4.41M in cash and equivalents against 29.43M in total debt, resulting in a net debt position of 12.83M. Total book value stands at -751,000.00, with working capital of -8.29M providing operational flexibility.

Cash & Cash Equivalents4.41M
Total Debt29.43M
Net Debt12.83M
Equity (Book Value)-751,000.00
Book Value Per Share-0.01
Working Capital-8.29M

Cash Flow

Cytosorbents Corporation produced -9.15M in operating cash flow over the past twelve months. After subtracting -436,000.00 in capital expenditures, free cash flow totaled -9.58M - equivalent to -0.15 per share.

Operating Cash Flow-9.15M
Capital Expenditures-436,000.00
Free Cash Flow-9.58M
FCF Per Share-0.15

Margins

Cytosorbents Corporation operates with a gross margin of 71.61, reflecting its pricing power and cost economics. The operating margin of -32.64 and net profit margin of -48.94 provide insight into operational efficiency.

Gross Margin71.61
Operating Margin-32.64
Pretax Margin-50.02
Profit Margin-48.94
EBITDA Margin-28.51

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-10.54
FCF Yield-37.10

Stock Splits

Cytosorbents Corporation's most recent stock split took place on September 8, 2026 with a 20:1 split ratio.

Last Split Date9/8/2026
Split Ratio20:1

Scores

Cytosorbents Corporation posts an Altman Z-Score of -12.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-12.84